FDAnews
www.fdanews.com/articles/142351-metabolex-announces-positive-results-from-its-clinical-study-of-arhalofenate-in-combination-with-febuxostat

Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat

December 8, 2011
Metabolex today announced positive results from its clinical study of arhalofenate in combination with febuxostat (Uloric), Takeda Pharmaceutical Company Limited). A key goal in the treatment of gout is to address the patient’s underlying hyperuricemia by treatment with drugs that lower serum uric acid (sUA). In the U.S., the goal of treatment is to reduce sUA levels to below 6 mg/dL.
PR Newswire